Key result
Metformin improves cardiovascular, metabolic, and reproductive outcomes by reducing insulin resistance in PCOS.
Why the study?
Early diagnosis and therapy of insulin resistance in PCOS are important to reduce reproductive, metabolic, and cardiovascular morbidity associated with the syndrome.
Do insulin sensitising-lowering agents improve reproductive, metabolic, and cardiovascular outcomes in women with polycystic ovary syndrome?
Population
Women with polycystic ovary syndrome
Comparison
Insulin-lowering agents (e.g. metformin) vs no treatment or other therapies
Design
Review
Authors
Loading...
Supports metformin consideration in PCOS; hypothesis-generating for cardiovascular benefits pending randomized trials.
Do insulin sensitising-lowering agents improve reproductive, metabolic, and cardiovascular outcomes in women with polycystic ovary syndrome?
Insulin-lowering agents such as metformin are beneficial in managing the reproductive, metabolic, and cardiovascular complications associated with polycystic ovary syndrome.
Wang et al. (2002) conducted a review in Polycystic ovary syndrome (PCOS). Insulin-lowering agents (metformin) was evaluated. Insulin sensitising-lowering agents, particularly metformin, reduce insulin resistance and improve reproductive, metabolic, and cardiovascular outcomes in women with polycystic ovary syndrome.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: